Moderna, Inc. $MRNA Shares Sold by Metis Global Partners LLC

Metis Global Partners LLC reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 44.2% in the second quarter, HoldingsChannel.com reports. The firm owned 8,052 shares of the company’s stock after selling 6,368 shares during the period. Metis Global Partners LLC’s holdings in Moderna were worth $222,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. S Bank Fund Management Ltd acquired a new stake in shares of Moderna in the first quarter valued at $25,000. TD Private Client Wealth LLC grew its holdings in Moderna by 348.8% during the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after acquiring an additional 743 shares during the period. Atlantic Union Bankshares Corp bought a new stake in Moderna in the second quarter worth about $26,000. SVB Wealth LLC acquired a new stake in Moderna in the 1st quarter valued at about $28,000. Finally, Whittier Trust Co. acquired a new stake in Moderna in the 2nd quarter valued at about $28,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MRNA. Evercore ISI set a $32.00 price objective on shares of Moderna in a research note on Friday, August 1st. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Monday, October 20th. JPMorgan Chase & Co. dropped their price target on Moderna from $26.00 to $25.00 and set an “underweight” rating on the stock in a report on Thursday, October 23rd. Bank of America cut their price objective on Moderna from $24.00 to $21.00 and set an “underperform” rating for the company in a research report on Monday. Finally, Citigroup reduced their price objective on Moderna from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $36.14.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $24.96 on Friday. The firm has a 50 day simple moving average of $25.93 and a 200 day simple moving average of $27.10. Moderna, Inc. has a 52 week low of $23.04 and a 52 week high of $48.92. The company has a market cap of $9.75 billion, a PE ratio of -3.09 and a beta of 2.02.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.15) by $1.64. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The company’s revenue was down 45.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.03 EPS. Moderna has set its FY 2025 guidance at EPS. On average, equities analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.